Login to Your Account

Rhythm's $25M Series B to Satisfy Clinical Data Appetite

By Catherine Shaffer
Staff Writer

Wednesday, June 13, 2012

A $25 million Series B financing disclosed Wednesday morning will bring the total amount invested in Rhythm Pharmaceuticals Inc. to $65 million, according to Bart Henderson, founder and president of the Boston-based company.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription